Last reviewed · How we verify
Lutetium Lu 177-Edotreotide
Lutetium Lu 177-Edotreotide is a Small molecule drug developed by ITM Solucin GmbH. It is currently in Phase 1 development. Also known as: 177Lu-edotreotide.
At a glance
| Generic name | Lutetium Lu 177-Edotreotide |
|---|---|
| Also known as | 177Lu-edotreotide |
| Sponsor | ITM Solucin GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (PHASE2)
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (PHASE3)
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. (PHASE1)
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (PHASE1)
- Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy (PHASE2)
- 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer (PHASE2)
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (PHASE3)
- Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lutetium Lu 177-Edotreotide CI brief — competitive landscape report
- Lutetium Lu 177-Edotreotide updates RSS · CI watch RSS
- ITM Solucin GmbH portfolio CI
Frequently asked questions about Lutetium Lu 177-Edotreotide
What is Lutetium Lu 177-Edotreotide?
Lutetium Lu 177-Edotreotide is a Small molecule drug developed by ITM Solucin GmbH.
Who makes Lutetium Lu 177-Edotreotide?
Lutetium Lu 177-Edotreotide is developed by ITM Solucin GmbH (see full ITM Solucin GmbH pipeline at /company/itm-solucin-gmbh).
Is Lutetium Lu 177-Edotreotide also known as anything else?
Lutetium Lu 177-Edotreotide is also known as 177Lu-edotreotide.
What development phase is Lutetium Lu 177-Edotreotide in?
Lutetium Lu 177-Edotreotide is in Phase 1.
Related
- Manufacturer: ITM Solucin GmbH — full pipeline
- Also known as: 177Lu-edotreotide
- Compare: Lutetium Lu 177-Edotreotide vs similar drugs
- Pricing: Lutetium Lu 177-Edotreotide cost, discount & access